

## ***Track record – Diseases – Interventions Vaccines***

**Review of tick-borne encephalitis and vaccines: clinical and economical aspects.** Smit R, Postma MJ. *Expert Rev Vaccines*. 2014 Nov 26;1-11. [Epub ahead of print]

**Cost-effectiveness of hepatitis A vaccination in Indonesia.** Suwantika AA, Beutels P, Postma MJ. *Hum Vaccin Immunother*. 2014;10(8):2342-9. doi: 10.4161/hv.29353.

**A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.** Vemer P, Postma MJ. *Hum Vaccin Immunother*. 2014 Jul;10(7):1841-9. doi: 10.4161/hv.29008.

**Expanding access to non-traditional vaccines: a perspective from Indonesia.** Suwantika AA, Postma MJ. *Expert Rev Vaccines*. 2014 Dec;13(12):1419-21. doi: 10.1586/14760584.2014.944165. Epub 2014 Aug 22.

**A few years later: Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.** Vemer P, Postma MJ. *Hum Vaccin Immunother*. 2014 May 8;10(8). [Epub ahead of print]

**Accelerating the introduction of rotavirus immunization in Indonesia.** Suwantika AA, Zakiyah N, Lestari K, Postma MJ. *Expert Rev Vaccines*. 2014 Apr;13(4):463-72. doi: 10.1586/14760584.2014.891940. Epub 2014 Mar 3. Review.

**Budget constraint and vaccine dosing: a mathematical modelling exercise.** Standaert BA, Curran D, Postma MJ. *Cost Eff Resour Alloc*. 2014 Jan 22;12(1):3. doi: 10.1186/1478-7547-12-3.

**RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population.** Meijboom MJ, Pouwels KB, Luytjes W, Postma MJ, Hak E. *Vaccine*. 2013 Dec 16;31(52):6254-60. doi: 10.1016/j.vaccine.2013.10.023. Epub 2013 Oct 19.

**Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation.** Kotsopoulos N, Connolly MP, Postma MJ, Hutubessy RC. *Vaccine*. 2013 Nov 4;31(46):5430-4. doi: 10.1016/j.vaccine.2013.09.002. Epub 2013 Sep 18.

**A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus.** Jiang Y, Gauthier A, Postma MJ, Ribassin-Majed L, Llargeron N, Bresse X. *Hum Vaccin Immunother*. 2013 Nov;9(11):2285-95. Epub 2013 Jul 23. Review.

**Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.** Gefenaite G, Tacken M, Bos J, Stirbu-Wagner I, Korevaar JC, Stolk RP, Wolters B, Bijl M, Postma MJ, Wilschut J, Nichol KL, Hak E. *PLoS One*. 2013 Jun 20;8(6):e66125. doi: 10.1371/journal.pone.0066125. Print 2013.

**Meningococcal serogroup A, C, W<sub>135</sub> and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.** Hepkema H, Pouwels KB, van der Ende A, Westra TA, Postma MJ. *PLoS One*. 2013 May 31;8(5):e65036. doi: 10.1371/journal.pone.0065036. Print 2013.

**Cost-effectiveness of rotavirus immunization in Indonesia: taking breastfeeding patterns into account.** Suwantika AA, Tu HA, Postma MJ. *Vaccine*. 2013 Jul 11;31(32):3300-7. doi: 10.1016/j.vaccine.2013.04.055. Epub 2013 May 21.

**Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples.** Postma MJ, Westra TA, Quilici S, Llargeron N. *Expert Rev Vaccines*. 2013 May;12(5):555-65. doi: 10.1586/erv.13.36. Review.

**Economic analysis of pandemic influenza mitigation strategies for five pandemic severity categories.** Kelso JK, Halder N, Postma MJ, Milne GJ. *BMC Public Health*. 2013 Mar 8;13:211. doi: 10.1186/1471-2458-13-211.

**Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.** Pouwels KB, Hak E, van der Ende A, Christensen H, van den Dobbelen GP, Postma MJ. *Hum Vaccin Immunother*. 2013 May;9(5):1129-38. doi: 10.4161/hv.23888. Epub 2013 Feb 13.

**Economics of vaccines revisited.** Postma MJ, Standaert BA. *Hum Vaccin Immunother*. 2013 May;9(5):1139-41. doi: 10.4161/hv.23447. Epub 2013 Jan 30.

**An update of "Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model".** Tu HA, Rozenbaum MH, de Boer PT, Noort AC, Postma MJ. *BMC Infect Dis*. 2013 Jan 30;13:54. doi: 10.1186/1471-2334-13-54.

**Impact of rotavirus vaccination on hospitalisations in Belgium: comparing model predictions with observed data.**

Standaert B, Gomez JA, Raes M, Debrus S, Velázquez FR, Postma MJ. *PLoS One*. 2013;8(1):e53864. doi: 10.1371/journal.pone.0053864. Epub 2013 Jan 18.

**Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.** de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ. *Vaccine*. 2013 Feb 18;31(9):1276-83. doi: 10.1016/j.vaccine.2012.12.067. Epub 2013 Jan 8.

**Contributing factors to influenza vaccine uptake in general hospitals: an explorative management questionnaire study from the Netherlands.** Riphagen-Dalhuisen J, Kuiphuis JC, Procé AR, Luytjes W, Postma MJ, Hak E. *BMC Public Health*. 2012 Dec 21;12:1101. doi: 10.1186/1471-2458-12-1101.

**Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around....** Rozenbaum MH, De Cao E, Westra TA, Postma MJ. *Expert Rev Vaccines*. 2012 Dec;11(12):1415-28. doi: 10.1586/erv.12.130. Review.

**Response on "RE: Cost-effectiveness of pertussis booster vaccination in the Netherlands".** Rozenbaum MH, Postma MJ. *Vaccine*. 2013 Apr 12;31(16):2024. doi: 10.1016/j.vaccine.2012.11.082. Epub 2012 Dec 11. No abstract available.

**Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions.** Farkouh RA, Klok RM, Postma MJ, Roberts CS, Strutton DR. *Expert Rev Vaccines*. 2012 Oct;11(10):1235-47. doi: 10.1586/erv.12.99. Epub 2012 Nov 21. Review.

**Dynamic modeling for pandemic influenza.** Postma MJ. *Expert Rev Vaccines*. 2012 May;11(5):543-6. doi: 10.1586/erv.12.30.

**Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.** Lugnér AK, van Boven M, de Vries R, Postma MJ, Wallinga J. *BMJ*. 2012 Jul 12;345:e4445. doi: 10.1136/bmj.e4445.

**Cost-effectiveness of pertussis booster vaccination in the Netherlands.** Rozenbaum MH, De Cao E, Postma MJ. *Vaccine*. 2012 Nov 26;30(50):7327-31. doi: 10.1016/j.vaccine.2012.06.026. Epub 2012 Jun 27.

**Comparatively low attendance during Human Papillomavirus catch-up vaccination among teenage girls in the Netherlands: Insights from a behavioral survey among parents.** Gefenaite G, Smit M, Nijman HW, Tami A, Drijfhout IH, Pascal A, Postma MJ, Wolters BA, van Delden JJ, Wilschut JC, Hak E. *BMC Public Health*. 2012 Jul 2;12:498. doi: 10.1186/1471-2458-12-498.

**On discounting of health gains from human papillomavirus vaccination: effects of different approaches.** Westra TA, Parouty M, Brouwer WB, Beutels PH, Rogoza RM, Rozenbaum MH, Daemen T, Wilschut JC, Boersma C, Postma MJ. *Value Health*. 2012 May;15(3):562-7. doi: 10.1016/j.jval.2012.01.005. Epub 2012 Mar 29.

**Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands.** Meijboom MJ, Rozenbaum MH, Benedictus A, Luytjes W, Kneyber MC, Wilschut JC, Hak E, Postma MJ. *Vaccine*. 2012 Jun 29;30(31):4691-700. doi: 10.1016/j.vaccine.2012.04.072. Epub 2012 May 2.

**A review of the literature on the economics of vaccination against TB.** Tu HA, Vu HD, Rozenbaum MH, Woerdenbag HJ, Postma MJ. *Expert Rev Vaccines*. 2012 Mar;11(3):303-17. doi: 10.1586/erv.11.197. Review.

**Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.** Tu HA, Rozenbaum MH, Coyte PC, Li SC, Woerdenbag HJ, Postma MJ. *Vaccine*. 2012 Feb 14;30(8):1521-8. doi: 10.1016/j.vaccine.2011.11.052. Epub 2011 Nov 23.

**Modelling the impact of extended vaccination strategies on the epidemiology of pertussis.** Rozenbaum MH, De Vries R, LE HH, Postma MJ. *Epidemiol Infect*. 2012 Aug;140(8):1503-14. doi: 10.1017/S0950268811002354. Epub 2011 Nov 24.

**Economic evaluations of rotavirus immunization for developing countries: a review of the literature.** Tu HA, Woerdenbag HJ, Kane S, Rozenbaum MH, Li SC, Postma MJ. *Expert Rev Vaccines*. 2011 Jul;10(7):1037-51. doi: 10.1586/erv.11.65. Review.

**Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world.** Postma MJ, Jit M, Rozenbaum MH, Standaert B, Tu HA, Hutubessy RC. *BMC Med*. 2011 Jul 8;9:84. doi: 10.1186/1741-7015-9-84. Review.

**Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model.** Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ; Consensus Group on Dutch Rotavirus Vaccination (CoRoVa-Group). BMC Public Health. 2011 Jun 10;11:462. doi: 10.1186/1471-2458-11-462.

Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence. Pechlivanoglou P, De Vries R, Daenen SM, Postma MJ. Pharmacoeconomics. 2011 Sep;29(9):737-51. doi: 10.2165/11588370-000000000-00000. Review.

**Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination.** Rozenbaum MH, Boersma C, Postma MJ, Hak E. Expert Rev Vaccines. 2011 Feb;10(2):187-99. doi: 10.1586/erv.10.163. Review.

**Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts.** Postma MJ, Milne G, Nelson EA, Pyenson B, Basili M, Coker R, Oxford J, Garrison LP Jr; PI Group. Expert Rev Anti Infect Ther. 2010 Dec;8(12):1431-9. doi: 10.1586/eri.10.136. Review.

**Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model.** de Vries R, Kretzschmar M, Schellekens JF, Versteegh FG, Westra TA, Roord JJ, Postma MJ. PLoS One. 2010 Oct 15;5(10):e13392. doi: 10.1371/journal.pone.0013392.

**Public vaccination programmes against hepatitis B in The Netherlands: assessing whether a targeted or a universal approach is appropriate.** Houweling H, Wittevrongel CF, Verweij M, Ruitenber E; National Immunisation Programme Review Committee of the Health Council of the Netherlands. Vaccine. 2010 Nov 16;28(49):7723-30. doi: 10.1016/j.vaccine.2010.09.068. Epub 2010 Oct 14.

**Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.** Rozenbaum MH, Hak E, van der Werf TS, Postma MJ. Clin Ther. 2010 Aug;32(8):1517-32. doi: 10.1016/j.clinthera.2010.06.016.

**Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.** Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelen G, Rodenburg GD, Hak E, Postma MJ. BMJ. 2010 Jun 2;340:c2509. doi: 10.1136/bmj.c2509.

**Criteria for inclusion of vaccinations in public programmes.** Houweling H, Verweij M, Ruitenber E; National Immunisation Programme Review Committee of the Health Council of the Netherlands. Vaccine. 2010 Apr 9;28(17):2924-31. doi: 10.1016/j.vaccine.2010.02.021. Epub 2010 Feb 26. Review.

**Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar).** Rozenbaum MH, Hoek AJ, Hak E, Postma MJ. Vaccine. 2010 Mar 11;28(12):2367-9. doi: 10.1016/j.vaccine.2010.01.005. Epub 2010 Jan 17.

**Mitigation of pandemic influenza: review of cost-effectiveness studies.** Lugnér AK, Postma MJ. Expert Rev Pharmacoecon Outcomes Res. 2009 Dec;9(6):547-58. doi: 10.1586/erp.09.56. Review.

**[Efficiency of human papillomavirus vaccination—estimates based on Dutch cost effectiveness analyses].** Westra TA, Daemen T, Postma MJ, Wilschut JC. Ned Tijdschr Geneesk. 2009;153:A356. Review. Dutch.

**Which factors are important in adults' uptake of a (pre)pandemic influenza vaccine? Zijtregtop EA, Wilschut J, Koelma N, Van Delden JJ, Stolk RP, Van Steenbergen J, Broer J, Wolters B, Postma MJ, Hak E. Vaccine. 2009 Dec 10;28(1):207-27. doi: 10.1016/j.vaccine.2009.09.099. Epub 2009 Oct 2.**

**Conclusions on (cost-)effectiveness of pertussis booster vaccination strategies highly dependent on selections made in evidence review.** Postma MJ, de Vries R, Roord J. Vaccine. 2009 Dec 9;27(52):7242-3. doi: 10.1016/j.vaccine.2009.08.077. Epub 2009 Sep 8.

**Cost-effectiveness analysis of Human Papillomavirus (HPV) vaccination in the Netherlands: recent publication reinforces favorable cost-effectiveness despite misleading conclusion.** Postma MJ. Vaccine. 2010 Jan 22;28(4):873-4. doi: 10.1016/j.vaccine.2009.10.109. Epub 2009 Nov 5. No abstract available.

**[Influenza vaccination of hospital healthcare staff from the perspective of the employer: a positive balance].** Hak E, Knol LM, Wilschut JC, Postma MJ. Ned Tijdschr Geneesk. 2010;154:A1188. Dutch.

**Cost-effectiveness of varicella vaccination programs: an update of the literature.** Rozenbaum MH, van Hoek AJ, Vegter S, Postma MJ. *Expert Rev Vaccines*. 2008 Aug;7(6):753-82. doi: 10.1586/14760584.7.6.753. Review.

**The value of ProMED-mail for the Early Warning Committee in the Netherlands: more specific approach recommended.** Zeldenrust ME, Rahamat-Langendoen JC, Postma MJ, van Vliet JA. *Euro Surveill*. 2008 Feb 7;13(6). pii: 8033.

**The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach.** Bos JM, Rietveld E, Moll HA, Steyerberg EW, Luytjes W, Wilschut JC, de Groot R, Postma MJ. *Vaccine*. 2007 Sep 28;25(39-40):6922-9. Epub 2007 Jul 30.

**Further evidence for favorable cost-effectiveness of elderly influenza vaccination.** Postma MJ, Baltussen RP, Palache AM, Wilschut JC. *Expert Rev Pharmacoecon Outcomes Res*. 2006 Apr;6(2):215-27. doi: 10.1586/14737167.6.2.215.

**Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.** Bos JM, Rümke HC, Welte R, Spanjaard L, van Alphen L, Postma MJ. *Pharmacoeconomics*. 2006;24(2):141-53.

**Do costs of varicella justify routine infant vaccination? Pharmacoeconomic and clinical considerations.** Postma MJ, Bos JM, Welte R, de Groot R, Luytjes W, Rümke HC, Beutels P. *Eur J Health Econ*. 2004 Feb;5(1):54-7. No abstract available.

**Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.** Postma MJ, Heijnen ML, Beutels P, Jager JC. *Expert Rev Vaccines*. 2003 Aug;2(4):477-82.

**Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands.** Bos JM, Rümke H, Welte R, Postma MJ. *Clin Ther*. 2003 Oct;25(10):2614-30.

**[Splenectomy and pneumococcal vaccination].** Postma MJ, Heijnen MA, de Vries R, Beutels P, Jager JC. *Ned Tijdschr Geneeskd*. 2003 Jun 7;147(23):1141-2; author reply 1142. Dutch. No abstract available.

**The use of modeling in the economic evaluation of vaccines.** Bos JM, Alphen Lv, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res*. 2002 Oct;2(5):443-55. doi: 10.1586/14737167.2.5.443.

**[Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].** Postma MJ, Heijnen ML, Beutels P, Jager JC. *Ned Tijdschr Geneeskd*. 2002 May 4;146(18):855-9. Dutch.

**Economic evaluations of adult pneumococcal vaccination strategies.** Beutels P, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res*. 2001 Oct;1(1):47-58. doi: 10.1586/14737167.1.1.47.